|
시장보고서
상품코드
2056330
출혈성 질환 치료 시장 보고서 : 유형, 약제 클래스별, 유통 채널, 최종사용자, 지역별(2026-2034년)Bleeding Disorders Treatment Market Report by Type, Drug Class, Distribution Channel, End User, and Region 2026-2034 |
||||||
세계의 출혈성 질환 치료 시장 규모는 2025년에 166억 달러에 달했습니다. 향후에 대해 IMARC Group은 2034년까지 시장 규모가 253억 달러에 달하며, 2026-2034년에 CAGR 4.68%로 성장할 것으로 예측하고 있습니다.
출혈성 질환에는 A형 및 B형 혈우병, 폰 빌레브란트병, 특발성 혈소판 감소성 자반병(ITP), 비타민 K 및 인자 II, V, VII, X, XII 결핍이 포함됩니다. 이들은 개인의 혈액 응고 과정을 억제하는 질환군입니다. 또한 외상 후 다량의 장기적인 출혈을 유발할 수도 있습니다. 증상으로는 월경시 과다출혈, 쉽게 멍이 들거나, 잦은 코피, 가벼운 상처로 인한 과다출혈, 관절내 출혈 등이 있습니다. 진단을 위해 전혈구수치(CBC), 혈소판 응집력, 출혈시간 등의 혈액검사를 시행합니다.
치료에는 아드레노크롬 모노세미칼바존, 망막출혈, 비출혈, 아미노카프론산, 아프로티닌, 철분제 등의 약물이 사용됩니다. 이러한 약물은 특정 증상을 완화하고 환자의 수명을 연장하는 데 도움이 될 수 있습니다. 출혈성 질환의 치료에는 수혈, 보충요법, 응고인자 및 혈장 주사도 포함됩니다.
출혈성 질환 치료제 시장 동향:
일반인의 출혈성 질환 유병률 증가와 이러한 질환에 취약한 고령 인구의 증가는 전 세계 시장을 촉진하는 주요 요인 중 하나입니다. 또한 출혈성 질환의 치료에 대한 경제적 지원을 제공하고 의료비를 절감하는 건강 보험 제도의 도입이 진행되고 있는 것도 시장에 긍정적인 영향을 미치고 있습니다. 또한 많은 국가의 정부 기관은 혈액 및 혈장 기증에 대한 인식 개선 활동을 진행하고 있습니다. 또한 헌혈 캠페인도 진행하고 있습니다.
여기에 효과적인 치료 옵션이 존재한다는 인식이 높아지면서 시장 전망은 더욱 밝아지고 있습니다. 또한 연구개발(R&D) 활동과 헬스케어 인프라 및 진단 기술의 눈부신 발전도 시장에 긍정적인 전망을 가져다 줄 것으로 예상됩니다.
이 보고서에서 답변하는 주요 질문:
- 지금까지의 글로벌 출혈성 질환 치료제 시장 동향은 어떠했으며, 향후 수년간 어떻게 변화하는가?
- COVID-19는 세계의 출혈성 질환 치료제 시장에 어떤 영향을 미쳤는가?
- 주요 지역 시장은 어디인가?
- 시장 유형별 시장 분석은?
- 약제 유형별 시장 현황은?
- 유통 채널별 시장 현황은?
- 최종사용자별 시장 분석은 어떻게 이루어지고 있는가?
- 이 산업의 밸류체인에서 각 단계는 어떤 역할을 하는가?
- 이 산업의 주요 촉진요인과 과제는 무엇인가?
- 세계의 출혈성 질환 치료 시장의 구조는 무엇이며, 주요 기업은 어디인가?
- 이 업계의 경쟁은 얼마나 치열한가?
목차
제1장 서문
제2장 조사 범위와 조사 방법
제3장 개요
제4장 서론
제5장 세계의 출혈성 질환 치료 시장
제6장 시장 내역 : 유형별
제7장 시장 내역 : 약제 클래스별
제8장 시장 내역 : 유통 채널별
제9장 시장 내역 : 최종사용자별
제10장 시장 내역 : 지역별
제11장 SWOT 분석
제12장 밸류체인 분석
제13장 Porter's Five Forces 분석
제14장 가격 분석
제15장 경쟁 구도
KSA 26.06.16The global bleeding disorders treatment market size reached USD 16.6 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 25.3 Billion by 2034, exhibiting a growth rate (CAGR) of 4.68% during 2026-2034.
Bleeding disorders involve hemophilia A and B, Von Willebrand disease, idiopathic thrombocytopenic purpura (ITP), and deficiencies of vitamin K and factors II, V, VII, X, and XII. They are a class of conditions that disrupt the blood clotting process in an individual. They can also lead to heavy and prolonged bleeding after an injury. They have symptoms, including heavy menstrual bleeding, easy bruising, frequent nosebleeds, excessive bleeding from minor cuts, and joint bleeding. They are diagnosed through blood tests of complete blood count (CBC), platelet aggregation, and bleeding time.
Their treatment comprises medications, including adrenochrome monosemicarbazone, retinal hemorrhage, epistaxis, aminocaproic acid, aprotinin, and iron supplements. These medications can aid in minimizing specific symptoms and prolonging the life of patients. Bleeding disorders treatment also includes blood transfusion, replacement therapy, and injections of a clotting factor and plasma.
Bleeding Disorders Treatment Market Trends:
The increasing prevalence of bleeding disorders among the masses and the rising geriatric population, which is more susceptible to these medical conditions, are among the key factors driving the market around the world. Moreover, the growing adoption of health insurance policies that provide financial assistance for bleeding disorders treatment and reduce healthcare expenses is influencing the market positively. In addition, governing agencies of numerous countries are generating awareness about blood and plasma donation. They are also undertaking initiatives to promote blood donation camps.
Apart from this, the increasing awareness about the availability of effective treatment alternatives is creating a positive outlook for the market. Furthermore, research and development (R&D) activities and considerable improvements in the healthcare infrastructure and diagnostic technologies are expected to provide a favorable outlook to the market.
Key Market Segmentation:
The research provides an analysis of the key trends in each sub-segment of the global bleeding disorders treatment market report, along with forecasts at the global, regional and country level from 2026-2034. Our report has categorized the market based on type, drug class, distribution channel and end user.
Breakup by Type:
- Hemophilia A
- Hemophilia B
- Von Willebrand Disease
- Other.
Breakup by Drug Class:
- Plasma-derived Coagulation Factor Concentrates
- Factor VIII
- Factor IX
- Factor for Von Willebrand Disease
- Activated Prothrombin Complex Concentrate
- Recombinant Coagulation Factor Concentrates
- Factor VIII
- Factor for Von Willebrand Disease
- Factor IX
- Desmopressin
- Antifibrinolytics
- Fibrin Sealants
- Other.
Breakup by Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Store.
Breakup by End User:
- Hospitals
- Clinics
- Academic and Research Institute.
Breakup by Region:
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Afric.
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being AbbVie Inc, Alnylam Pharmaceuticals Inc., Bayer AG, CSL Behring (CSL Limited), Grifols S.A., Johnson & Johnson, Novo Nordisk A/S, Octapharma AG, Pfizer Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited and Wellona Pharma.
Key Questions Answered in This Report:
- How has the global bleeding disorders treatment market performed so far and how will it perform in the coming years?
- What has been the impact of COVID-19 on the global bleeding disorders treatment market?
- What are the key regional markets?
- What is the breakup of the market based on the type?
- What is the breakup of the market based on the drug class?
- What is the breakup of the market based on the distribution channel?
- What is the breakup of the market based on the end user?
- What are the various stages in the value chain of the industry?
- What are the key driving factors and challenges in the industry?
- What is the structure of the global bleeding disorders treatment market and who are the key players?
- What is the degree of competition in the industry?
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
5 Global Bleeding Disorders Treatment Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
6 Market Breakup by Type
- 6.1 Hemophilia A
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
- 6.2 Hemophilia B
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
- 6.3 Von Willebrand Disease
- 6.3.1 Market Trends
- 6.3.2 Market Forecast
- 6.4 Others
- 6.4.1 Market Trends
- 6.4.2 Market Forecast
7 Market Breakup by Drug Class
- 7.1 Plasma-derived Coagulation Factor Concentrates
- 7.1.1 Market Trends
- 7.1.2 Key Segments
- 7.1.2.1 Factor VIII
- 7.1.2.2 Factor IX
- 7.1.2.3 Factor for Von Willebrand Disease
- 7.1.2.4 Activated Prothrombin Complex Concentrate
- 7.1.3 Market Forecast
- 7.2 Recombinant Coagulation Factor Concentrates
- 7.2.1 Market Trends
- 7.2.2 Key Segments
- 7.2.2.1 Factor VIII
- 7.2.2.2 Factor for Von Willebrand Disease
- 7.2.2.3 Factor IX
- 7.2.3 Market Forecast
- 7.3 Desmopressin
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
- 7.4 Antifibrinolytics
- 7.4.1 Market Trends
- 7.4.2 Market Forecast
- 7.5 Fibrin Sealants
- 7.5.1 Market Trends
- 7.5.2 Market Forecast
- 7.6 Others
- 7.6.1 Market Trends
- 7.6.2 Market Forecast
8 Market Breakup by Distribution Channel
- 8.1 Hospital Pharmacies
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
- 8.2 Retail Pharmacies
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
- 8.3 Online Stores
- 8.3.1 Market Trends
- 8.3.2 Market Forecast
9 Market Breakup by End User
- 9.1 Hospitals
- 9.1.1 Market Trends
- 9.1.2 Market Forecast
- 9.2 Clinics
- 9.2.1 Market Trends
- 9.2.2 Market Forecast
- 9.3 Academic and Research Institutes
- 9.3.1 Market Trends
- 9.3.2 Market Forecast
10 Market Breakup by Region
- 10.1 North America
- 10.1.1 United States
- 10.1.1.1 Market Trends
- 10.1.1.2 Market Forecast
- 10.1.2 Canada
- 10.1.2.1 Market Trends
- 10.1.2.2 Market Forecast
- 10.1.1 United States
- 10.2 Asia-Pacific
- 10.2.1 China
- 10.2.1.1 Market Trends
- 10.2.1.2 Market Forecast
- 10.2.2 Japan
- 10.2.2.1 Market Trends
- 10.2.2.2 Market Forecast
- 10.2.3 India
- 10.2.3.1 Market Trends
- 10.2.3.2 Market Forecast
- 10.2.4 South Korea
- 10.2.4.1 Market Trends
- 10.2.4.2 Market Forecast
- 10.2.5 Australia
- 10.2.5.1 Market Trends
- 10.2.5.2 Market Forecast
- 10.2.6 Indonesia
- 10.2.6.1 Market Trends
- 10.2.6.2 Market Forecast
- 10.2.7 Others
- 10.2.7.1 Market Trends
- 10.2.7.2 Market Forecast
- 10.2.1 China
- 10.3 Europe
- 10.3.1 Germany
- 10.3.1.1 Market Trends
- 10.3.1.2 Market Forecast
- 10.3.2 France
- 10.3.2.1 Market Trends
- 10.3.2.2 Market Forecast
- 10.3.3 United Kingdom
- 10.3.3.1 Market Trends
- 10.3.3.2 Market Forecast
- 10.3.4 Italy
- 10.3.4.1 Market Trends
- 10.3.4.2 Market Forecast
- 10.3.5 Spain
- 10.3.5.1 Market Trends
- 10.3.5.2 Market Forecast
- 10.3.6 Russia
- 10.3.6.1 Market Trends
- 10.3.6.2 Market Forecast
- 10.3.7 Others
- 10.3.7.1 Market Trends
- 10.3.7.2 Market Forecast
- 10.3.1 Germany
- 10.4 Latin America
- 10.4.1 Brazil
- 10.4.1.1 Market Trends
- 10.4.1.2 Market Forecast
- 10.4.2 Mexico
- 10.4.2.1 Market Trends
- 10.4.2.2 Market Forecast
- 10.4.3 Others
- 10.4.3.1 Market Trends
- 10.4.3.2 Market Forecast
- 10.4.1 Brazil
- 10.5 Middle East and Africa
- 10.5.1 Market Trends
- 10.5.2 Market Breakup by Country
- 10.5.3 Market Forecast
11 SWOT Analysis
- 11.1 Overview
- 11.2 Strengths
- 11.3 Weaknesses
- 11.4 Opportunities
- 11.5 Threats
12 Value Chain Analysis
13 Porters Five Forces Analysis
- 13.1 Overview
- 13.2 Bargaining Power of Buyers
- 13.3 Bargaining Power of Suppliers
- 13.4 Degree of Competition
- 13.5 Threat of New Entrants
- 13.6 Threat of Substitutes
14 Price Analysis
15 Competitive Landscape
- 15.1 Market Structure
- 15.2 Key Players
- 15.3 Profiles of Key Players
- 15.3.1 AbbVie Inc
- 15.3.1.1 Company Overview
- 15.3.1.2 Product Portfolio
- 15.3.1.3 Financials
- 15.3.1.4 SWOT Analysis
- 15.3.2 Alnylam Pharmaceuticals Inc.
- 15.3.2.1 Company Overview
- 15.3.2.2 Product Portfolio
- 15.3.2.3 Financials
- 15.3.2.4 SWOT Analysis
- 15.3.3 Bayer AG
- 15.3.3.1 Company Overview
- 15.3.3.2 Product Portfolio
- 15.3.3.3 Financials
- 15.3.3.4 SWOT Analysis
- 15.3.4 CSL Behring (CSL Limited)
- 15.3.4.1 Company Overview
- 15.3.4.2 Product Portfolio
- 15.3.5 Grifols S.A.
- 15.3.5.1 Company Overview
- 15.3.5.2 Product Portfolio
- 15.3.5.3 Financials
- 15.3.5.4 SWOT Analysis
- 15.3.6 Johnson & Johnson
- 15.3.6.1 Company Overview
- 15.3.6.2 Product Portfolio
- 15.3.6.3 Financials
- 15.3.6.4 SWOT Analysis
- 15.3.7 Novo Nordisk A/S
- 15.3.7.1 Company Overview
- 15.3.7.2 Product Portfolio
- 15.3.7.3 Financials
- 15.3.7.4 SWOT Analysis
- 15.3.8 Octapharma AG
- 15.3.8.1 Company Overview
- 15.3.8.2 Product Portfolio
- 15.3.8.3 SWOT Analysis
- 15.3.9 Pfizer Inc.
- 15.3.9.1 Company Overview
- 15.3.9.2 Product Portfolio
- 15.3.9.3 Financials
- 15.3.9.4 SWOT Analysis
- 15.3.10 Sanofi S.A.
- 15.3.10.1 Company Overview
- 15.3.10.2 Product Portfolio
- 15.3.10.3 Financials
- 15.3.10.4 SWOT Analysis
- 15.3.11 Takeda Pharmaceutical Company Limited
- 15.3.11.1 Company Overview
- 15.3.11.2 Product Portfolio
- 15.3.11.3 Financials
- 15.3.11.4 SWOT Analysis
- 15.3.12 Wellona Pharma
- 15.3.12.1 Company Overview
- 15.3.12.2 Product Portfolio
- 15.3.1 AbbVie Inc
